Abstract | BACKGROUND: METHODS: Ninety UAP patients with elevated liver enzymes (higher than 3-fold the upper limits of normal caused by statins) were randomly divided into 3 groups: withdrawal of simvastatin (group A), continued taking of simvastatin (group B) and switching to Xuezhikang capsules (group C). RESULTS: CONCLUSIONS: KEY WORDS:
|
Authors | Fang Cui, Youliang Zhang, Qingmin Wei, Cuihua Liu, Junhui Wang, Meng Zhang |
Journal | Acta Cardiologica Sinica
(Acta Cardiol Sin)
Vol. 31
Issue 1
Pg. 66-71
(Jan 2015)
ISSN: 1011-6842 [Print] China (Republic : 1949- ) |
PMID | 27122848
(Publication Type: Journal Article)
|